FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

Figure 3

(a) SUVmax values (numerical) and changes in SUVmax (bars) after completion of neoadjuvant treatment for each patient. (b) depicts changes in tumor size from baseline to end of treatment. Histopathologic responders are illustrated in orange. Three of four histopathologic responders showed decreases in SUVmax by $\ge$60% from baseline to followup scan. One histopathologic responder with a 38% decrease in FDG uptake from baseline to followup showed an SUVmax value after completion of neoadjuvant therapy of $<$2.5 and was therefore correctly classified. Size changes in response to treatment were marginal.

(a) $∆$SUV Baseline-Followup (bars) and SUVmax at Followup (numerical)

(b) $∆$Size Baseline-Followup